UAE Next Generation Sequencing Market Industry Size, Share, Trends, Opportunity, and Forecast Segmented By Product (Consumables, Platforms, Services), By Technology (Sequencing by Synthesis, lon Semiconductor Sequencing, Sequencing by Ligation, Single Molecule Real Time Sequencing, Others), By Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research, Others), By End User (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Others), by region, and Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 23.57 Million
CAGR (2026-2031)	15.02%
Fastest Growing Segment	Reproductive Health
Largest Market	Abu Dhabi
Market Size (2031)	USD 54.58 Million

Market Overview

The UAE Next Generation Sequencing Market will grow from USD 23.57 Million in 2025 to USD 54.58 Million by 2031 at a 15.02% CAGR. Next Generation Sequencing constitutes an advanced methodology that enables the rapid and comprehensive analysis of genetic material to identify variants associated with diseases. The primary driver supporting the United Arab Emirates market is the robust government mandate to establish a national genomic infrastructure for preventive healthcare. According to the Department of Health Abu Dhabi, in 2025, the Emirati Genome Program had collected over 800,000 genetic samples to advance precision medicine capabilities. This centralized support significantly accelerates the procurement and utilization of sequencing technologies across the region.

A significant challenge that could impede market expansion is the scarcity of specialized workforce talent required for complex bioinformatics data interpretation. The analysis of massive genomic datasets demands advanced technical proficiency that remains limited within the local labor pool. This deficiency in skilled professionals creates bottlenecks in processing clinical data and restricts the seamless integration of sequencing diagnostics into standard patient care protocols.

Key Market Drivers

Strategic Public-Private Partnerships and Global Collaborations are fundamentally reshaping the UAE Next Generation Sequencing Market by accelerating the transfer of cutting-edge genomic technologies into local clinical practice. These alliances enable healthcare providers to leverage global expertise in bioinformatics and data analysis, establishing the region as a hub for advanced diagnostics. For instance, the integration of genomic data into broader digital health ecosystems is a key priority for major stakeholders to enhance patient accessibility. According to M42, October 2025, in a press release regarding a strategic collaboration with the Medical Tourism Association, the initiative projects scaling its digital platform to 3 million users by the end of the year, facilitating wider access to genomic-backed healthcare services.

The Growing Demand for Prenatal and Newborn Screening Programs acts as a second critical driver, significantly propelled by government directives aimed at reducing the burden of hereditary conditions. Mandatory testing protocols are rapidly normalizing the use of sequencing tools for early detection and preventive family planning. According to Gulf News, April 2025, in an article regarding the national mandatory program, over 1,000 Emiratis had undergone premarital genetic testing since the mandate's implementation in January. This surge in screening volume directly correlates with the expansion of specialized treatment facilities capable of interpreting complex genetic data. Consequently, according to Burjeel Holdings, March 2025, in the 'FY 2024 Financial Results', revenue from the medical oncology segment increased by 39.6% year-on-year, reflecting the growing reliance on precision medicine and diagnostics.

Download Free Sample Report

Key Market Challenges

The scarcity of specialized workforce talent, particularly in bioinformatics and genomic data interpretation, stands as a critical impediment to the growth of the UAE Next Generation Sequencing Market. While the physical infrastructure for sequencing is expanding, the intricate analysis required to translate massive genomic datasets into clinical applications demands a level of technical proficiency that is currently limited in the local labor supply. This widening gap between data generation capabilities and analytical capacity creates severe operational bottlenecks, preventing healthcare providers from delivering timely diagnostic results and stalling the transition of precision medicine from research environments to standard clinical practice.

This human capital deficit directly restricts the market's ability to meet ambitious national healthcare objectives. The inability to process genetic data efficiently limits the utility of the sequencing investments already made, thereby slowing the adoption rate of these technologies. According to the Department of Health – Abu Dhabi, in 2025, the authority released a strategic framework estimating that genomic interventions could reduce the burden of chronic illnesses by 20 to 30 percent. However, the realization of such significant market outcomes is heavily constrained by the current lack of qualified professionals necessary to operationalize these advanced diagnostic protocols.

Key Market Trends

Market players are increasingly deploying sovereign AI platforms to automate the analysis of massive datasets from the Emirati Genome Program, moving beyond simple sequencing to AI-driven variant discovery and predictive disease modeling. This convergence allows for the identification of population-specific genetic markers at a scale previously unattainable, fundamentally shifting the sector's focus from data generation to computational interpretation. According to The National News, June 2024, in the article 'UAE genome programme to transform medical care for Emiratis', the analysis of initial cohorts by the Emirates Genome Council identified more than five million novel gene variants that were previously uncatalogued in global databases. This rapid accumulation of unique genomic data is necessitating advanced algorithmic infrastructures to validate these variants for clinical application.

Healthcare providers are concurrently beginning to integrate pharmacogenomic testing into treatment protocols for chronic diseases, utilizing patient genetic profiles to predict drug responses and minimize adverse reactions in a clinical setting. This trend marks a critical transition of genomic data from research repositories into routine bedside care, facilitated by the interoperability of national health information exchanges. According to the Department of Health – Abu Dhabi, September 2024, in the announcement regarding the 'availability of pharmacogenomic (PGx) reports', the integration of these genetic insights into the Malaffi platform aims to avert 20 to 30 percent of adverse drug reactions for eligible program participants. Such operationalization ensures that sequencing investments directly translate into enhanced therapeutic efficacy and improved patient safety standards across the network.

Segmental Insights

Reproductive Health represents the fastest growing segment in the UAE Next Generation Sequencing market due to the rising demand for early genetic diagnosis. This expansion is largely fueled by the increasing utilization of non-invasive prenatal testing and pre-implantation genetic screening to manage the prevalence of hereditary disorders in the region. The growth is further supported by initiatives from the Ministry of Health and Prevention that encourage comprehensive pre-marital and prenatal screenings to reduce genetic anomalies. These factors collectively drive the adoption of sequencing technologies, establishing reproductive health as a primary area of development within the local diagnostic sector.

Regional Insights

Abu Dhabi maintains the leading position in the UAE Next Generation Sequencing market, supported by strategic government mandates and substantial investment in healthcare infrastructure. The region benefits from the regulatory oversight of the Department of Health – Abu Dhabi, which actively promotes genomic research and personalized medicine. A primary driver of this market dominance is the execution of the Emirati Genome Program, which accelerates the adoption of sequencing technologies for population health management. This concentration of research initiatives and diagnostic facilities enables Abu Dhabi to function as the central hub for genomic services within the United Arab Emirates.

Recent Developments

• In June 2025, M42 announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to introduce advanced liquid biopsy testing capabilities within the United Arab Emirates. This initiative involved integrating a specialized genomic profiling solution into the company's local testing infrastructure to facilitate non-invasive cancer diagnosis and biomarker detection. The partnership aimed to improve clinical decision-making by providing precise genetic insights from simple blood draws, thereby expanding access to personalized oncology care. This development marked a significant advancement in the region's diagnostic landscape, enabling faster and more accurate treatment selection for patients across a broad range of cancer types.
• In August 2024, the Dubai Police General Command established a partnership with Oxford Nanopore Technologies to adopt advanced DNA sequencing solutions for forensic and security applications. This collaboration involved the deployment of rapid and accessible sequencing devices to enhance the department's capabilities in pathogen detection and forensic science. The agreement also focused on joint research and development initiatives, as well as specialized training programs for personnel to effectively utilize nanopore technology. By integrating these tools, the organization aimed to set new standards in crime scene analysis and public safety, demonstrating the expanding utility of next-generation sequencing beyond traditional clinical settings in the region.
• In June 2024, the Department of Health – Abu Dhabi signed a Memorandum of Understanding with Illumina to integrate advanced genomic capabilities into the emirate's healthcare system. This collaboration was established to accelerate the application of precision medicine by leveraging next-generation sequencing technologies and identifying genetic causes for rare and chronic diseases. The agreement focused on developing a skilled local workforce and establishing a robust infrastructure to support the widespread adoption of clinical genomics. Through this partnership, the organizations aimed to enhance patient outcomes by incorporating genomic insights into standard medical care and public health strategies across the United Arab Emirates.
• In January 2024, M42 entered into a strategic collaboration with the Broad Institute of MIT and Harvard and Microsoft to advance the United Arab Emirates’ capabilities in precision health and genomic research. This partnership focused on leveraging the Terra platform to enhance the country's clinico-genomic infrastructure, facilitating secure data access and analysis for scientific discovery. The initiative aimed to integrate multimodal data sets, including genomic and clinical information, to support the development of personalized medicine solutions. By utilizing cloud-based technologies, the collaboration sought to accelerate the diagnosis and treatment of diseases, positioning the company as a key player in the global life sciences ecosystem.

Key Market Players

• Oxford Nanopore UAE
• Agiomix Labs
• Illumina UAE
• Thermo Fischer Scientific UAE
• PerkinElmer UAE
• Alliance Global UAE
• Oxford Nanopore Technologies plc
• Bio-Rad Laboratories, Inc.
• Genomatix Software GmbH
• 10x Genomics, Inc.

By Product	By Technology	By Application	By End User	By Region
Consumables Platforms Services	Sequencing by Synthesis lon Semiconductor Sequencing Sequencing by Ligation Single Molecule Real Time Sequencing Others	Biomarkers & Cancer Diagnostics Reproductive Health Personalized Medicine Agriculture & Animal Research Others	Academic & Clinical Research Centers Pharmaceutical & Biotechnology Companies Hospitals & Clinics Others	Dubai Abu Dhabi Sharjah Rest of UAE

Report Scope:

In this report, the UAE Next Generation Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• UAE Next Generation Sequencing Market, By Product:

• Consumables
• Platforms
• Services

• UAE Next Generation Sequencing Market, By Technology:

• Sequencing by Synthesis
• lon Semiconductor Sequencing
• Sequencing by Ligation
• Single Molecule Real Time Sequencing
• Others

• UAE Next Generation Sequencing Market, By Application:

• Biomarkers & Cancer
• Diagnostics
• Reproductive Health
• Personalized Medicine
• Agriculture & Animal Research
• Others

• UAE Next Generation Sequencing Market, By End User:

• Academic & Clinical Research Centers
• Pharmaceutical & Biotechnology Companies
• Hospitals & Clinics
• Others

• UAE Next Generation Sequencing Market, By Region:

• Dubai
• Abu Dhabi
• Sharjah
• Rest of UAE